{"preliminary_commentary":{"by_channel":{"x_thread":7,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02047513\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["nab-paclitaxel","gemcitabine"]],"indication":"resectable pancreatic ductal adenocarcinoma","name":"NEONAX","nct_id":"NCT02047513","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neonax-nct02047513. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NEONAX","arms":[{"description":"neoadjuvant chemotherapy (8 weeks) preceding surgery (3 weeks after completion of chemotherapy) followed by adjuvant chemotherapy (16 weeks, begin within 12 weeks after surgery)","label":"perioperative nab-paclitaxel/gemcitabine","type":"EXPERIMENTAL"},{"description":"Surgery followed by adjuvant chemotherapy (24 weeks, begin within 12 weeks after surgery), follow-up per patient: Until end of study or death","label":"adjuvant nab-paclitaxel/gemcitabine","type":"EXPERIMENTAL"}],"collaborators":["Celgene","ClinAssess GmbH"],"completion_date":{"date":"2022-10","type":"ACTUAL"},"conditions":["Resectable Pancreatic Cancer","Ductal Adenocarcinoma of the Pancreas"],"enrollment":{"count":127,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"perioperative nab-paclitaxel/gemcitabine","otherNames":[],"type":"DRUG"},{"name":"adjuvant nab-paclitaxel/gemcitabine","otherNames":[],"type":"DRUG"}],"last_update":"2023-06-15","lead_sponsor":"AIO-Studien-gGmbH","official_title":"Neoadjuvant Plus Adjuvant or Only Adjuvant Nab-Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer: A Prospective, Randomized, Controlled, Phase II Study of the AIO (Working Group for Medical Oncology From the German Cancer Society) Pancreatic Cancer Group","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Time to Disease free survival (DFS)","timeFrame":"18 months after randomization"}],"references":[{"citation":"Seufferlein T, Uhl W, Kornmann M, Algul H, Friess H, Konig A, Ghadimi M, Gallmeier E, Bartsch DK, Lutz MP, Metzger R, Wille K, Gerdes B, Schimanski CC, Graupe F, Kunzmann V, Klein I, Geissler M, Staib L, Waldschmidt D, Bruns C, Wittel U, Fichtner-Feigl S, Daum S, Hinke A, Blome L, Tannapfel A, Kleger A, Berger AW, Kestler AMR, Schuhbaur JS, Perkhofer L, Tempero M, Reinacher-Schick AC, Ettrich TJ. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. 2023 Jan;34(1):91-100. doi: 10.1016/j.annonc.2022.09.161. Epub 2022 Oct 7.","pmid":"36209981","type":"DERIVED"},{"citation":"Ettrich TJ, Berger AW, Perkhofer L, Daum S, Konig A, Dickhut A, Wittel U, Wille K, Geissler M, Algul H, Gallmeier E, Atzpodien J, Kornmann M, Muche R, Prasnikar N, Tannapfel A, Reinacher-Schick A, Uhl W, Seufferlein T. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC Cancer. 2018 Dec 29;18(1):1298. doi: 10.1186/s12885-018-5183-y.","pmid":"30594153","type":"DERIVED"}],"start_date":{"date":"2015-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer","url":"https://clinicaltrials.gov/study/NCT02047513"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neonax-nct02047513"}